8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Mar 9, 2026·SEC
Mineralys Therapeutics, Inc.(MLYS)Earnings, Financials & Key Ratios
MLYS•NASDAQ
$30.12
$2B mkt cap·Price updated May 6, 2026
AboutMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Show more
- Revenue$0
- EBITDA-$171M+11.3%
- Net Income-$155M+13.0%
- EPS (Diluted)-2.29+37.4%
- ROE-36.91%+55.1%
- ROIC-46.45%+56.7%
MLYS Key Insights
Mineralys Therapeutics, Inc. (MLYS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 114.2% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 39.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MLYS Price & Volume
Mineralys Therapeutics, Inc. (MLYS) stock price & volume — 10-year historical chart
Loading chart...
MLYS Growth Metrics
Mineralys Therapeutics, Inc. (MLYS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.04%
Return on Capital
10 Years-349.63%
5 Years-349.63%
3 Years-59.48%
Last Year-40.72%
MLYS Recent Earnings
Mineralys Therapeutics, Inc. (MLYS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
Mar 12, 2026EPS
$0.40
Est $0.52
+22.5%
Revenue
—
Q4 2025
Nov 10, 2025EPS
$0.52
Est $0.66
+21.2%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.66
Est $0.78
+15.4%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.79
Est $1.02
+22.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.40vs $0.52+22.5% | — |
| Q4 2025 | Nov 10, 2025 | $0.52vs $0.66+21.2% | — |
| Q3 2025 | Aug 12, 2025 | $0.66vs $0.78+15.4% | — |
| Q2 2025 | May 12, 2025 | $0.79vs $1.02+22.5% | — |
Based on last 12 quarters of dataView full earnings history →
MLYS Peer Comparison
Mineralys Therapeutics, Inc. (MLYS) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CORT | 5.6B | 52.15 | 63.60 | 12.79% | 6.23% | 7.5% | 0.01 | |
 SPRB | 79.4M | 57.87 | -1.14 | -100% | -203.99% | 0.02 | ||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 MNKD | 1.1B | 3.56 | 178 | 22.23% | -6.63% | |||
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 XOMA | 493.33M | 41.60 | 28.49 | 83.06% | 56.4% | 31.88% | 1.57 | |
 CHRS | 212.02M | 1.75 | 1.22 | -84.2% | 398.43% | 7.89% | 0.02 |
Compare MLYS vs Peers
Mineralys Therapeutics, Inc. (MLYS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MLYS Income Statement
Mineralys Therapeutics, Inc. (MLYS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 59K | 28K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -59K▲ 0% | -28K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 2.94M | 18.73M | 31.48M | 84.66M | 192.4M | 170.6M | 171.47M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 532K | 2.42M | 5.23M | 14.3M | 23.82M | 38.59M | 52.99M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 2.41M | 16.31M | 26.25M | 70.36M | 168.58M | 132.01M | 118.5M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.94M▲ 0% | -18.73M▼ 536.3% | -31.48M▼ 68.1% | -84.66M▼ 168.9% | -192.4M▼ 127.3% | -170.6M▲ 11.3% | -171.5M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -536.26% | -68.11% | -168.93% | -127.27% | 11.33% | - |
| EBITDA | -3.31M | -19.38M | -31.48M | -84.66M | -192.36M | -170.54M | -171.45M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -485.35% | -62.42% | -168.93% | -127.22% | 11.34% | 14.89% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 43K | 59K | 44K |
| EBIT | -3.31M | -19.38M | -31.48M | -84.66M | -192.4M | -170.6M | -121.96M |
| Net Interest Income | -115K | -27K | 0 | 12.76M | 14.59M | 15.95M | 13.71M |
| Interest Income | 0 | 0 | 1.68M | 12.76M | 14.59M | 15.95M | 13.71M |
| Interest Expense | 115K | 27K | 1.68M | 0 | 0 | 0 | 0 |
| Other Income/Expense | -483K | -683K | 1.68M | 12.76M | 14.59M | 15.95M | 19.72M |
| Pretax Income | -3.43M▲ 0% | -19.41M▼ 466.5% | -29.8M▼ 53.5% | -71.9M▼ 141.3% | -177.81M▼ 147.3% | -154.65M▲ 13.0% | -151.78M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -3.43M▲ 0% | -19.41M▼ 466.5% | -29.8M▼ 53.5% | -71.9M▼ 141.3% | -177.81M▼ 147.3% | -154.65M▲ 13.0% | -151.78M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -466.49% | -53.54% | -141.28% | -147.31% | 13.02% | 19.49% |
| Net Income (Continuing) | -3.43M | -19.41M | -29.8M | -71.9M | -177.81M | -154.65M | -151.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.74▲ 0% | -3.89▼ 425.7% | -5.77▼ 48.3% | -1.99▲ 65.5% | -3.66▼ 83.9% | -2.29▲ 37.4% | -1.83▲ 0% |
| EPS Growth % | - | -425.68% | -48.33% | 65.51% | -83.92% | 37.43% | 45.04% |
| EPS (Basic) | -0.74 | -3.89 | -5.77 | -1.99 | -3.66 | -2.29 | - |
| Diluted Shares Outstanding | 4.63M | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M | 82.83M |
| Basic Shares Outstanding | 4.63M | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M | 82.83M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
MLYS Balance Sheet
Mineralys Therapeutics, Inc. (MLYS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.47M | 11.12M | 112.81M | 249.1M | 205.35M | 661.39M | 652.47M |
| Cash & Short-Term Investments | 1.41M | 10.61M | 110.11M | 236.57M | 198.19M | 656.63M | 112.78M |
| Cash Only | 1.41M | 10.61M | 87.7M | 49.3M | 114.09M | 172.92M | 112.78M |
| Short-Term Investments | 0 | 0 | 22.41M | 187.26M | 84.1M | 483.71M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 2.7M | 12.54M | 7.16M | 4.75M | 539.69M |
| Total Non-Current Assets | 20K | 3K | 1.63M | 2.53M | 552K | 420K | 392K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 53K | 38K | 32K |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 2.48M | 0 | 0 | 0 |
| Other Non-Current Assets | 20K | 3K | 1.63M | 51K | 499K | 382K | 1.32M |
| Total Assets | 1.49M▲ 0% | 11.13M▲ 648.7% | 114.44M▲ 928.7% | 251.64M▲ 119.9% | 205.9M▼ 18.2% | 661.81M▲ 221.4% | 652.86M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 648.65% | 928.69% | 119.88% | -18.17% | 221.42% | 434.41% |
| Total Current Liabilities | 5.08M | 5.05M | 8.07M | 10.48M | 14.65M | 15.11M | 14.72M |
| Accounts Payable | 529K | 763K | 1.91M | 601K | 479K | 2.02M | 1.12M |
| Days Payables Outstanding | - | - | - | - | - | 12.48K | 24.17K |
| Short-Term Debt | 4.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 313K | 665K | 1.6M | 0 | 7.56M | 14.72M |
| Current Ratio | 0.29x | 2.20x | 13.98x | 23.76x | 14.02x | 43.76x | 43.76x |
| Quick Ratio | 0.29x | 2.20x | 13.98x | 23.76x | 14.02x | 43.76x | 43.76x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 29M | 158.64M | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 29M | 158.64M | 0 | 0 | 0 | 0 |
| Total Liabilities | 5.08M | 34.05M | 166.71M | 10.48M | 14.65M | 15.11M | 14.72M |
| Total Debt | 4.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 3.09M | -10.61M | -87.7M | -49.3M | -114.09M | -172.92M | -112.78M |
| Debt / Equity | - | - | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.66x |
| Interest Coverage | -28.79x | -717.81x | -18.78x | - | - | - | - |
| Total Equity | -3.6M▲ 0% | -22.93M▼ 537.3% | -52.27M▼ 128.0% | 241.15M▲ 561.4% | 191.26M▼ 20.7% | 646.69M▲ 238.1% | 638.14M▲ 0% |
| Equity Growth % | - | -537.34% | -128% | 561.37% | -20.69% | 238.13% | 476.34% |
| Book Value per Share | -0.78 | -4.60 | -10.12 | 6.66 | 3.94 | 9.56 | 7.70 |
| Total Shareholders' Equity | -3.6M | -22.93M | -52.27M | 241.15M | 191.26M | 646.69M | 638.14M |
| Common Stock | 1K | 1K | 1K | 4K | 5K | 8K | 8K |
| Retained Earnings | -3.6M | -23.01M | -52.81M | -124.71M | -302.52M | -457.17M | -496.51M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -251.64M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MLYS Cash Flow Statement
Mineralys Therapeutics, Inc. (MLYS) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.46M | -14.56M | -29.22M | -81.17M | -166.31M | -142.42M | -142.42M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -491.11% | -100.71% | -177.79% | -104.89% | 14.37% | 98.94% |
| Net Income | -3.43M | -19.41M | -29.8M | -71.9M | -177.81M | -154.65M | -151.78M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 43K | 59K | 50K |
| Stock-Based Compensation | 1K | 80K | 455K | 5.06M | 11.34M | 19.32M | 22.23M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 482K | 684K | -649K | -6.87M | -9.4M | -9.88M | -15.52M |
| Working Capital Changes | 480K | 4.08M | 772K | -7.47M | 9.52M | 2.73M | 8.62M |
| Change in Receivables | 0 | 0 | 0 | -355K | 424K | -166K | -218K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | -402K |
| Cash from Investing | 0 | 0 | -21.76M | -160.47M | 114.96M | -389.75M | -341.82M |
| Capital Expenditures | 0 | 0 | 0 | 0 | -96K | -15K | -15K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 3.83M | 23.81M | 128.02M | 203.25M | 116.14M | 591M | 425.99M |
| Debt Issued (Net) | 3.85M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | -20K | 23.81M | 128.02M | 202.99M | 116.06M | 591M | 395.13M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -1.63M | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 258K | 83K | 0 | 30.87M |
| Net Change in Cash | 1.41M▲ 0% | 9.25M▲ 556.7% | 77.04M▲ 732.6% | -38.4M▼ 149.8% | 64.79M▲ 268.7% | 58.83M▼ 9.2% | -52.23M▲ 0% |
| Free Cash Flow | -2.46M▲ 0% | -14.56M▼ 491.1% | -29.22M▼ 100.7% | -81.17M▼ 177.8% | -166.41M▼ 105.0% | -142.43M▲ 14.4% | -136.41M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -491.11% | -100.71% | -177.79% | -105.01% | 14.41% | 29.21% |
| FCF per Share | -0.53 | -2.92 | -5.65 | -2.24 | -3.43 | -2.11 | -2.11 |
| FCF Conversion (FCF/Net Income) | 0.72x | 0.75x | 0.98x | 1.13x | 0.94x | 0.92x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MLYS Key Ratios
Mineralys Therapeutics, Inc. (MLYS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -76.13% | -82.24% | -36.91% | -27.92% |
| Return on Invested Capital (ROIC) | - | - | -244.77% | -107.28% | -46.45% | -46.45% |
| Debt / Equity | - | - | - | - | - | 0.00x |
| Interest Coverage | -717.81x | -18.78x | - | - | - | - |
| FCF Conversion | 0.75x | 0.98x | 1.13x | 0.94x | 0.92x | 0.90x |
MLYS SEC Filings & Documents
Mineralys Therapeutics, Inc. (MLYS) SEC filings — annual & quarterly reports (10-K, 10-Q)
MLYS Frequently Asked Questions
Mineralys Therapeutics, Inc. (MLYS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mineralys Therapeutics, Inc. (MLYS) grew revenue by 0.0% over the past year. Growth has been modest.
Mineralys Therapeutics, Inc. (MLYS) reported a net loss of $151.8M for fiscal year 2025.
Dividend & Returns
Mineralys Therapeutics, Inc. (MLYS) has a return on equity (ROE) of -36.9%. Negative ROE indicates the company is unprofitable.
Mineralys Therapeutics, Inc. (MLYS) had negative free cash flow of $136.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More MLYS
Mineralys Therapeutics, Inc. (MLYS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates